[PDF] Top 20 Decitabine in the treatment of acute myeloid leukemia in elderly patients
Has 10000 "Decitabine in the treatment of acute myeloid leukemia in elderly patients" found on our website. Below are the top 20 most common "Decitabine in the treatment of acute myeloid leukemia in elderly patients".
Decitabine in the treatment of acute myeloid leukemia in elderly patients
... of patients with acute myeloid leukemia (AML) are elderly and have a poor prognosis despite induction ...therapy. Decitabine, a DNA-hypomethylating agent that induces ... See full document
9
Decitabine Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy
... therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than ...with Decitabine and Vorinostat have had varying degrees of ...Combined ... See full document
18
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
... Abstract: Decitabine is a hydrophilic drug that acts by hypomethylating ...DNA. Decitabine is used in Europe for the treatment of acute myeloid leukemia (AML) in patients ... See full document
16
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
... Abstract: Acute myeloid leukemia (AML) is a hematopoietic stem cell disorder that affects approximately 14,000 persons each year in the ...the treatment of AML over the past decades have led ... See full document
10
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
... by decitabine is S-phase dependent, and is more extensive in actively cycling cells ...phase leukemia cells into S phase and caused leukemia cells response to ...of decitabine and cytarabine ... See full document
11
Decitabine as a First Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
... the patients was ...24 patients, and the median number of cycles was four (range, ...Thirteen patients dropped out because of death, no or loss of response, patient refusal, or transfer to another ... See full document
8
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
... drug treatment methods for AML include chemotherapy, targeted therapy, and ...on patients’ ...older patients due to their low ...and decitabine and DAG, all of which are effective to some ... See full document
9
Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
... and decitabine are hypomethylating agents used in the treatment of de novo MDS and AML, and they may have a role for relapse prophylaxis or treatment after ...10 patients revealed that ... See full document
25
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis
... the treatment of the elderly population with ...treat elderly patients with AML found an increased OS when compared to conventional or best care (me- dian OS ...of elderly ... See full document
6
<p>Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease</p>
... the treatment response, bone marrow aspiration was performed every month within 6 months after trans- ...in patients with previously normal BM or evidence of extramedullary ...of acute and chronic ... See full document
9
Emerging therapies for acute myeloid leukemia
... in elderly patients with AML ...of patients with FLT3-ITD) but resulted in higher treatment-related ...untreated elderly patients [57, ...AML patients, median EFS was ... See full document
14
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
... the patients receiving DAC therapy during follow-up ...DAC treatment was also more effective in those RR-AML patients who had a poor prognosis such as high-risk cytogenetics or WT1 or FLT-3 ...few ... See full document
8
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
... [17]. Patients with CR required normalization of peripheral blood counts with less than 5% blasts in bone ...marrow. Patients with PR required all of the hematologic values for CR but with a decrease of at ... See full document
11
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
... of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid ... See full document
5
Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine
... 95 patients (73 patients with primary leukemia and 22 patients with leukemia secondary to myelodysplastic or myeloproliferative syn- ...AML patients. Furthermore, the previous ... See full document
11
Case Report Hemophagocytic lymphohistiocytosis in patients with acute myeloid leukemia: a report of three cases and literature review
... marrow hyperplasia, reduced granulocyte pro- liferation, increased primitive granulocytes, increased mononuclear cells, increased ratio of primitive and immature mononuclear cells (54%), decreased proliferation of ... See full document
5
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
... AML patients and confers a poor risk status characterized by an increased relapse rate and poor overall survival ...AML patients relapsing after allogeneic stem cell transplantation (SCT) have very limited ... See full document
10
Original Article Decreased miR-218 expression predicts unfavorable prognosis in de novo acute myeloid leukemia
... AML patients especially with t (8;16) ...and treatment choice of newly diagnosed de novo AML ...CN-AML patients are long-term survivors ...AML patients with normal karyotypes ...optimize ... See full document
9
Midostaurin: an emerging treatment for acute myeloid leukemia patients
... diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY ... See full document
11
Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis
... Eighty-eight patients were randomized to one of the following groups: continuous high-dose lenalidomide (n = 15), sequential azacitidine and lenalidomide (n = 39), or azacitidine only (n = ...34). Patients ... See full document
12
Related subjects